+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

COVID-19 Nucleic Acid Amplification Tests (NAATs) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update

  • PDF Icon

    Report

  • 22 Pages
  • December 2023
  • Region: Global
  • GlobalData
  • ID: 5923669
The Medical Devices sector report, “COVID 19 Nucleic Acid Amplification Tests (NAATs) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update' provides comprehensive information about the COVID 19 Nucleic Acid Amplification Tests (NAATs) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

NAAT involves amplification of specific nucleic acid sequences of SARS-CoV-2 virus by targeting specific nucleic acid sequences. NAAT exhibits better sensitivity in comparison to antigen identification methods. Multiple targets are used in PCR to detect the different types of SARS-Cov-2.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the COVID 19 Nucleic Acid Amplification Tests (NAATs) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of COVID 19 Nucleic Acid Amplification Tests (NAATs) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to Buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Identify and understand important and diverse types of COVID 19 Nucleic Acid Amplification Tests (NAATs) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 COVID 19 Nucleic Acid Amplification Tests (NAATs) Overview
3 Products under Development
3.1 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
3.2 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Territory
3.3 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Regulatory Path
3.4 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Ongoing Clinical Trials
4 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products under Development by Companies
4.1 COVID 19 Nucleic Acid Amplification Tests (NAATs) Companies - Pipeline Products by Stage of Development
4.2 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
5 COVID 19 Nucleic Acid Amplification Tests (NAATs) Companies and Product Overview
5.1 Age Labs AS Company Overview
5.1.1 Age Labs AS Pipeline Products & Ongoing Clinical Trials Overview
5.2 Chengdu One-Chip Biotechnology Co Ltd Company Overview
5.2.1 Chengdu One-Chip Biotechnology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
6 COVID 19 Nucleic Acid Amplification Tests (NAATs)- Recent Developments
6.1 Nov 29, 2023: BioSkryb Genomics Appoints Genomics Industry Veteran Ram Laxman as Chief Commercial Officer
6.2 Oct 30, 2023: Cepheid Receives 510(K) Clearance For Xpert Xpress CoV-2 Plus Test
6.3 Mar 17, 2023: When time matters, rapid point of care testing can support treatment decisions
6.4 Mar 15, 2023: Cepheid receives Health Canada Licence for Xpert Xpress CoV-2 plus
7 Appendix
7.1 Methodology
7.2 About the Publisher
7.3 Contact the Publisher
7.4 Disclaimer
List of Tables
  • COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
  • COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Territory
  • COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Regulatory Path
  • COVID 19 Nucleic Acid Amplification Tests (NAATs) - Ongoing Clinical Trials
  • COVID 19 Nucleic Acid Amplification Tests (NAATs) Companies - Pipeline Products by Stage of Development
  • COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
  • Glossary
List of Figures
  • COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
  • COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Territory
  • COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Regulatory Path
  • COVID 19 Nucleic Acid Amplification Tests (NAATs) - Ongoing Clinical Trials

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Age Labs AS
  • Chengdu One-Chip Biotechnology Co Ltd